News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Abstral EU Success Continues. Orexo AB Receives Sales Milestone of 3.3 MEUR.
May 25, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (STO:ORX) announced today that accumulated sales of Abstral has surpassed 65 MEUR, which was faster than earlier anticipated and results in a 3.3 MEUR milestone payment from ProStrakan.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
IPO
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
July 16, 2026
·
4 min read
·
Tristan Manalac
Psychedelics
J&J sees Spravato sales surge as psychedelic competitors loom
July 16, 2026
·
2 min read
·
Tristan Manalac
Layoffs
Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharma
July 16, 2026
·
6 min read
·
Angela Gabriel
Manufacturing
Amid $55B US manufacturing push, J&J turns to streamlining its pharma supply chain
July 15, 2026
·
1 min read
·
Gabrielle Masson